Seegene has launched the Global Million Clinical Study (GMCS), a landmark initiative involving one million test cases to evaluate and establish new disease-specific testing standards using syndromic PCR approaches. The study aims to generate real-world scientific evidence to support better-informed clinical decision-making worldwide.
Study Scale and Objectives
The GMCS is designed to assess the clinical utility of comprehensive syndromic PCR testing, which enables the simultaneous detection of multiple pathogens in a single test. Scheduled to begin in South Korea and expand to healthcare institutions globally, the project will accumulate large-scale testing data on major infectious diseases. The ultimate goal is to create a scientific basis for new global testing standards, ensuring that patients everywhere have access to the best available diagnostics regardless of their country or region.
Seegene Recognized as Impactful Company
Seegene was recently named one of TIME's “The World’s Most Impactful Companies of 2026,” highlighting its efforts to address high-priority global challenges through its core business. The company's work on the GMCS underscores its commitment to improving diagnostic accuracy and public health outcomes worldwide.
Technology and Data Analytics Platform
For the GMCS, Seegene will provide STAgora™, a real-time testing data analytics platform. This platform supports statistical analysis of pathogen prevalence and infection trends across different disease types and geographic regions, enabling researchers to gain insights that were previously difficult to capture through conventional testing methods.
Beyond Conventional Testing
The GMCS aims to go beyond traditional targeted testing by evaluating the clinical value of comprehensive PCR testing. This approach can detect previously undetected pathogens, co-infections, genotypes, and regional and seasonal epidemiological patterns. According to Seegene, the study will analyze real-world testing data that has been challenging to capture fully with conventional methods alone.
Focus on Major Infectious Diseases
The study will initially focus on three major infectious disease categories: reproductive tract infections, respiratory tract infections, and gastrointestinal tract infections. By evaluating disease-specific diagnostic strategies, the GMCS aims to provide additional testing insights beyond existing methods and assess how this information can support clinical decision-making.
Creating Evidence-Based Standards
Seegene notes that while state-of-the-art PCR diagnostic technologies can provide consistent diagnostic capability, actual testing practices vary depending on each country's healthcare environment. Target pathogens, recommended testing protocols, and reimbursement policies differ according to national clinical guidelines and healthcare systems. This means patients with the same disease may have access to different levels and scopes of diagnostic testing. The GMCS seeks to address these disparities by generating evidence-based insights that can inform new, universally applicable testing standards.
